InsightsIntothePathogenesis：见解的发病机制.pdfVIP

MECHANISMS OF OPHTHALMIC DISEASE SECTION EDITOR: LEONARD A. LEVIN, MD, PhD Insights Into the Pathogenesis of Thyroid-Associated Orbitopathy Evolving Rationale for Therapy Michael Kazim, MD; Robert A. Goldberg, MD; Terry J. Smith, MD ttempts to understand the pathogenesis of thyroid-associated orbitopathy (TAO) have failed, in part because of confounding features associated with its variable clinical pre- sentation. In the absence of a more complete insight into disease mechanisms, no spe- Acific and effective therapy can be developed. It is our view that much of the informa- tion necessary to unravel the complexities of TAO and therefore formulate rational therapy has already been gathered. CLINICAL FEATURES OF TAO threatens vision and requires immediate medical attention. The active phase of TAO Thyroid-associated orbitopathy varies typically lasts 1 year, after which most pa- widely in its pattern of presentation. Gen- tients improve.1,7 Residual stigmas of the eralizations about this disease are not par- disease often persist after the active phase ticularly useful when treatment plans are resolves, but few patients require surgical developed for an individual